Study on the Bioavailability of SHR0302 in Healthy Subjects
NCT ID: NCT04712838
Last Updated: 2021-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2021-03-15
2021-04-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group A
SHR0302
Group A subjects were given oral F1 、F2 and F3 version SHR0302
group B
SHR0302
Group B subjects were given oral F1 、F3 and F2 version SHR0302
group C
SHR0302
Group C subjects were given oral F2 、F1 and F3 version SHR0302
group D
SHR0302
Group D subjects were given oral F2 、F3 and F1 version SHR0302
group E
SHR0302
Group E subjects were given oral F3 、F1 and F2 version SHR0302
group F
SHR0302
Group F subjects were given oral F3 、F2 and F1 version SHR0302
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SHR0302
Group A subjects were given oral F1 、F2 and F3 version SHR0302
SHR0302
Group B subjects were given oral F1 、F3 and F2 version SHR0302
SHR0302
Group C subjects were given oral F2 、F1 and F3 version SHR0302
SHR0302
Group D subjects were given oral F2 、F3 and F1 version SHR0302
SHR0302
Group E subjects were given oral F3 、F1 and F2 version SHR0302
SHR0302
Group F subjects were given oral F3 、F2 and F1 version SHR0302
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 18\~45 years old (including both ends, subject to when signing the informed consent form), healthy male
3. Weight ≥ 50 kg, and body mass index (BMI): 19\~26 kg/m2 (including both ends)
4. Those who have signed the informed consent and have no birth plan within 6 months after the last administration, and agree to take effective contraceptive measures
5. Able to communicate well with the researcher, and understand and comply with the requirements of this research
Exclusion Criteria
2. Those who have participated in clinical trials of any drugs and medical devices within six months before screening (subject to the signed informed consent form)
3. Subjects with any systemic inflammatory disease or autoimmune disease
4. Subjects with a history of recurrent herpes zoster, disseminated herpes zoster or disseminated herpes simplex
5. Subjects with a history of malignant tumors
6. Subjects with mental or neurological diseases, unwilling to communicate or have language barriers, unable to fully understand and cooperate
7. Those who have a history of tuberculosis (TB) within six months before screening, or have clinical or imaging evidence of active or occult TB
8. Routine blood examination during the screening period: white blood cell count \<3.0×109/L and/or neutrophil count \<1.5×109/L
9. Subjects Those with serum creatinine\> 1.5 mg/dL (133 μmol/L) at the time of screening
10. At the time of screening, 12-ECG check QTcF\>450 ms or there are other abnormal conditions judged by the investigator to be clinically meaningful
11. Those who are positive for hepatitis B surface antigen, hepatitis C antibodies, syphilis antibodies, and HIV antibodies
12. Those who smoked more than 5 cigarettes daily in the 3 months before screening and cannot stop using any Tobacco products
13. Those who drink regularly in the 6 months before screening, drink more than 14 units of alcohol per week (1 unit = 285 mL of beer, 25 mL of spirits, or 100 mL of wine) and cannot stop using any alcoholic products during the trial; those who have a positive alcohol breath test
14. People who have a history of drug abuse, drug dependence or a positive urine drug abuse screening before administration, including: morphine, methamphetamine (methamphetamine), ketamine, cocaine, ecstasy (dimethylene) Dioxyamphetamine), cannabis (tetrahydrocannabinolic acid)
15. Those who have had any surgery within 6 months before screening
16. Infections that require antimicrobial (virus, bacterial, fungal, and parasitic infections) treatment that occurred within 4 weeks before screening
17. Donated blood (or blood loss) within 3 months before screening and donated blood (or blood loss) ≥400 mL, or received blood transfusion
18. Those who have had any acute disease that has been determined by the investigator to be clinically significant within 1 month before screening
19. Those who have taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or health products within 14 days before taking the study drugs; those who plan to take non-study drugs or health products during the trial period
20. The 48 hours before the first dose until the end of the study, the subject refused to stop any methyl yellow Purine beverages or foods, such as coffee, tea, cola, chocolate, etc.; The 7 days before the first dose until the end of the study, the subject refused to stop using any beverages or foods containing grapefruit; there are special dietary requirements that cannot be consistent Eaters
21. Physical examination, vital signs, laboratory examinations, chest X-ray or chest CT, abdominal ultrasound and other abnormal and clinically meaningful examination results
22. The researcher believes that there are other subjects who are not suitable for participating in the research
18 Years
45 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jiangsu HengRui Medicine Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Xuanwu Hospital Beijing,Capital Medical University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SHR0302-108
Identifier Type: -
Identifier Source: org_study_id